Evidence map›Paper›PMID 31905703›Full record

ArticleMolecules (Basel, Switzerland)2019

Adenosine Receptor Agonists Exhibit Anti-Platelet Effects and the Potential to Overcome Resistance to P2Y

Nina Wolska, Magdalena Boncler, Dawid Polak, Joanna Wzorek, Tomasz Przygodzki, Magdalena Gapinska, Cezary Watala, Marcin Rozalski

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. AInternational review of neurobiology · 2023
    Article
  4. Article
  5. Adenosine: a partially discovered medicinal agent.Future journal of pharmaceutical sciences · 2021
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Nina WolskaDepartment of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Faculty of Health Sciences, Medical University of Lodz, Mazowiecka 6/8, 92-235 Lodz, Poland.ORCID 0000-0002-8982-9741
Magdalena BonclerDepartment of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Faculty of Health Sciences, Medical University of Lodz, Mazowiecka 6/8, 92-235 Lodz, Poland.ORCID 0000-0002-4860-5338
Dawid PolakDepartment of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Faculty of Health Sciences, Medical University of Lodz, Mazowiecka 6/8, 92-235 Lodz, Poland.
Joanna WzorekDepartment of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Faculty of Health Sciences, Medical University of Lodz, Mazowiecka 6/8, 92-235 Lodz, Poland.
Tomasz PrzygodzkiDepartment of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Faculty of Health Sciences, Medical University of Lodz, Mazowiecka 6/8, 92-235 Lodz, Poland.
Magdalena GapinskaLaboratory of Microscopic Imaging and Specialized Biological Techniques, Faculty of Biology and Environmental Protection, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland.ORCID 0000-0002-3125-7920
Cezary WatalaDepartment of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Faculty of Health Sciences, Medical University of Lodz, Mazowiecka 6/8, 92-235 Lodz, Poland.
Marcin RozalskiDepartment of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Faculty of Health Sciences, Medical University of Lodz, Mazowiecka 6/8, 92-235 Lodz, Poland.ORCID 0000-0001-5189-1243
Medical University of Lodz · PLUniversity of Łódź · PL

Funding

Fundacja na rzecz Nauki Polskiej TEAM/2016-1/8Uniwersytet Medyczny w Lodzi 502-03/6-020-01/502-64-125-18
6 · The paper itself

Abstract

Large inter-individual variation in platelet response to endogenous agonists and pharmacological agents, including resistance to antiplatelet therapy, prompts a search for novel platelet inhibitors and development new antithrombotic strategies. The present in vitro study evaluates the beneficial effects of three adenosine receptor (AR) agonists (regadenoson, LUF 5835 and NECA), different in terms of their selectivity for platelet adenosine receptors, when used alone and in combination with P2Y

Indexed as

Adenosine MonophosphateDrug ResistanceFemaleHumansMalePlatelet AggregationPlatelet Aggregation InhibitorsPrasugrel HydrochloridePurinergic P1 Receptor AgonistsReceptors, Purinergic P2Y12ThrombosisAdenosine MonophosphatecangrelorP2RY12 protein, humanPlatelet Aggregation InhibitorsPrasugrel HydrochloridePurinergic P1 Receptor AgonistsReceptors, Purinergic P2Y12adenosine receptoradenosine receptor agonistanti-platelet therapyP2Y12 antagonistplatelet

Identifiers

PMID31905703
PMCPMC6982709
OpenAlexW2997212980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.